MSD
pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib
Biodrugs/ Drugs
Cancer
Pembrolizumab (in Combination with MK-6482 and Lenvatinib, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment for ccRCC
3Phase III in Spain,
2Phase II,
1Phase I